MiNK Therapeutics
INKT

MiNK Therapeutics (INKT) analyst forecast and price target

Analyst forecast

Buy

Consensus of 2 analyst ratings

Buy
2
Hold
0
Sell
0

Recent analyst ratings

FirmActionRatingPrice targetDate
HC Wainwright & Co.MaintainedBuy$35.00May 18, 2026
HC Wainwright & Co.MaintainedBuy$35.00Apr 1, 2026
HC Wainwright & Co.UpgradedNeutral → Buy$35.00Aug 15, 2025
HC Wainwright & Co.DowngradedBuy → Neutral$35.00Jul 15, 2025
William BlairDowngradedOutperform → Market PerformJul 14, 2025
HC Wainwright & Co.MaintainedBuy$35.00Mar 18, 2025
HC Wainwright & Co.MaintainedBuy$35.00 from $9.00Feb 25, 2025
HC Wainwright & Co.MaintainedBuy$9.00Nov 15, 2024
BairdMaintainedOutperform$4.00 from $8.00Nov 15, 2024
HC Wainwright & Co.MaintainedBuy$9.00Oct 9, 2024
HC Wainwright & Co.MaintainedBuy$9.00Aug 13, 2024
HC Wainwright & Co.MaintainedBuy$9.00May 14, 2024
HC Wainwright & Co.MaintainedBuy$9.00 from $10.00Mar 21, 2024
HC Wainwright & Co.MaintainedBuy$10.00Aug 10, 2023
HC Wainwright & Co.MaintainedBuy$10.00 from $7.00May 12, 2023
HC Wainwright & Co.MaintainedBuy$7.00Apr 19, 2023

Frequently asked questions

  • Is INKT a buy, sell, or hold?

    Analysts covering MiNK Therapeutics currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.

  • What is the latest analyst rating on INKT?

    On May 18, 2026, HC Wainwright & Co. maintained MiNK Therapeutics at Buy with a price target of $35.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.